Results 11 to 20 of about 795 (119)

食管鳞状细胞癌 5q23.1-q23.2 杂合性丢失的研究

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2004
【目的】分析食管癌5号染色体长臂上5q23.1-q23.2区域的杂合性丢失,为食管癌候选抑癌基因定位缩小范围。【方法】用PCR银染技术,检测50例配对食管鳞状细胞癌标本6个微卫星标记的杂合性丢失情况。【结果】在检测的微卫星标记中,D5S471和D5S592杂合性丢失率高达47%和41%。【结论】D5S471和D5S592附近可能存在食管癌的候选抑癌基因。
李小东
doaj   +1 more source

中国南方食管鳞癌D5S107和D5S408杂合性丢失与微卫星不稳定性

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2008
【目的】研究中国南方食管癌高发地区(潮汕地区)食管鳞癌5号染色体长臂(5q)部分微卫星标记的杂合性丢失(LOH)和微卫星不稳定(MSI),为食管鳞癌相关抑癌基因的定位提供依据。【方法】采用PCR银染技术,检测58例配对食管鳞状细胞癌标本多个微卫星标记(D5S107;SHGS31088;D5S816;D5S625和D5S408)的杂合性丢失和微卫星不稳定。【结果】SHGS31088,D5S816和D5S625杂合性丢失率和微卫星不稳定都较低;而D5S107和D5S408的杂合性丢失率分别为48.5%和34.
李小东   +7 more
doaj   +1 more source

食管癌中真核翻译起始因子5A2的表达及与预后的相关性 [PDF]

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2017
【目的】探讨真核翻译起始因子5A2(EIF5A2)在食管鳞状细胞癌(ESCC)中的表达及其临床意义。【方法】运用 免疫组化方法,检测 EIF5A2 蛋白在 135 例食管鳞状细胞癌中的表达水平,分析其与临床病理参数之间的相关性及其预 后价值。【结果】在135例ESCC患者中高表达68例,Pearson′s 卡方检验结果显示EIF5A2在ESCC中的表达水平与T分期 (P = 0.006)、淋巴结转移(P = 0.031)、临床分期(P = 0.026)显著相关 ...
陈杰伟   +5 more
doaj   +2 more sources

Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma [PDF]

open access: yes, 2023
Background and purpose: Immunohistochemistry (IHC) expression of programmed death ligand-1 (PD-L1) is the most widely used biomarker for predicting the efficacy of esophageal cancer immunotherapy, and accurate and reliable PD-L1 testing is crucial for ...
CHEN Lijun, WANG Yichen, ZHENG Qiang, WANG Yue, JIN Yan, LI Yuan
core   +1 more source

RSRC1 inhibits the proliferation and metastasis of ESCC by targeting PTEN/PI3K/AKT pathway [PDF]

open access: yes, 2023
Objective To explore the role of arginine-and serine-rich coiled coil 1(RSRC1) in the proliferation and metastasis of esophageal squamous cell carcinoma(ESCC). Methods The expression of PTEN in ESCC was detected by biogenic analysis.
Zhou Jiatian, Shang Guansheng, Zhang Cong, Jiang Dexiong, Yuan Dongdong, Tang Dengyao, Zhou Jiang
core   +1 more source

Deciphering the suppressive effects of CBX8 on prostate cancer cell invasion [PDF]

open access: yes, 2023
Objective·To elucidate the regulatory mechanisms of the chromobox protein homolog 8 (CBX8) in prostate cancer metastasis from transcriptome and epigenetic modification perspectives.Methods·The correlation between the expression of CBX proteins and ...
LAO Yimin   +3 more
core   +1 more source

Research on T Lymphocyte Subsets and NK Cells Activity in Peripheral Blood of Hypopharyngeal Squamous Cell Carcinoma [PDF]

open access: yes, 2017
目的:分析下咽鳞状细胞癌患者外周血T淋巴细胞亚群和NK细胞活性情况,旨在为相关研究工作提供参考资料。方法:择取2011年6月-2016年5月本院收治的95例下咽鳞状细胞癌病患为病例组,另取此期间内来本院接受健康检查的72例志愿者为正常组。使用流式细胞仪对病患开展相关检查,分析病例组与正常组的淋巴细胞亚群、NK活性情况以及不同临床分期的下咽癌病患外周血T淋巴细胞亚群以及NK细胞活性之间的关系。结果:与正常组相比,病例组的NK细胞、总B淋巴细胞、总T淋巴细胞、辅助/抑制T细胞、辅助T细胞偏低(P0.05 ...
刘存山   +7 more
core   +1 more source

Expression and clinical significance of PLA2G2A in kidney renal papillary cell carcinoma [PDF]

open access: yes, 2023
Objective·To investigate the expression and clinical significance of phospholipase A2 Group ⅡA (PLA2G2A) in kidney renal papillary cell carcinoma (KIRP), and provide new ideas for seeking KIRP targets.Methods·The expression level of PLA2G2A in pan-cancer
LI Fang   +5 more
core   +1 more source

食管鳞癌患者唾液菌群的研究 [PDF]

open access: yes, 2020
【目的】分析食管鳞癌患者(ESCC组)与健康对照组(HC组)唾液菌群多样性,筛选出食管鳞癌患者唾液中特异性细菌。【方法】收集50例食管鳞癌患者和40例健康对照者的唾液标本,提取总DNA,用PCR扩增16SrDNAV4区,进行高通量测序,将测序数据进行OUT聚类,物种注释及多样性分析。【结果】多样性分析表明ESCC组和HC组整体唾液菌群的多样性及组成方面存在差异(但>0.05),物种分析表明ESCC组以奈瑟菌属(Neisseria)、梭杆菌属(Fusobacterium)、嗜血杆菌属 ...
位俊敏   +7 more
core  

Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events [PDF]

open access: yes, 2022
Programmed cell death protein-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are a group of immune checkpoint inhibitors. Since May 2006, there have been 10 immune checkpoint inhibitors targeting PD-1 and PD-L1 for tumor treatment. Although PD-
YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng
core   +1 more source

Home - About - Disclaimer - Privacy